Once fully implemented, these contracts represent approximately $1.7 million of Annual Recurring Revenue.
Xybion Corporation, a global low-code SaaS company that enables digital transformation in highly regulated industries like Life Sciences, today announced that its preclinical laboratory solution, Pristima XD, was deployed recently to help several pharmaceutical companies, Contract Research Organizations (CROs) and Biotechnology companies to improve productivity by digitizing lab operations.
Read More: Allego Recognized By “Boston Business Journal” As A Best Place To Work For Fourth Year…
- A global pharmaceutical company located in Germany launched Pristima XD for end-to-end lab operations to simplify user experience, provide more flexibility, and standardize on a single IT framework.
- A large Gene & Cell Therapy lab with a prestigious, top tier university has implemented Pristima XD to speed up their strategy to develop and commercialize genetic based therapeutics.
- A biopharmaceutical company is deploying Pristima XD to digitize their preclinical study labs to help accelerate and expand the production of novel products for the treatment of rare and ultra-rare diseases.
- A leading biomedical research and services organization implemented Pristima XD and Labwise XD to digitize their laboratories requiring compliance with Good Laboratory Practice regulations of US Food and Drug Administration
- Three CROs selected Pristima XD to streamline protocol management, study management and quality management operations.
“Pristima XD enables companies to digitally manage, track, and control business processes and data. This AI and machine learning capable software helps the users capture, manage, report, retrieve, and predict results better. Our ability to decrease study time to speed up innovation and significantly reduce study costs are unique benefits Xybion brings to the Life Sciences industry,” said Pradip K. Banerjee, Ph.D., Chairman & CEO of Xybion.
Read More: Qumulo Announces Native Support for Amazon Nimble Studio
“I’m seeing a vast change in our customer behavior. Historically, preclinical business was a fragmented segment with multiple point solutions supporting the lab operation. We are very excited to see the adoption of platform-based solutions now. Many of our new customers are already preparing to add more modules to enhance their automation capabilities,” says Kamal Biswas, President and COO of Xybion.